Magnetic Resonance–Guided Prostate Stereotactic Body Radiation Therapy With Daily Online Plan Adaptation: Results of a Prospective Phase 1 Trial and Supplemental Cohort

[1]  J. Torres-Roca,et al.  Non-Adaptive MR-Guided Radiotherapy for Prostate SBRT: Less Time, Equal Results , 2021, Journal of clinical medicine.

[2]  F. Lagerwaard,et al.  Dose accumulation for personalized stereotactic MR-guided adaptive radiation therapy in prostate cancer. , 2021, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[3]  A. Kishan,et al.  Stereotactic Body Radiotherapy for High-Risk Localized CARcinoma of the Prostate (SHARP) Consortium: Analysis of 344 Prospectively Treated Patients. , 2020, International journal of radiation oncology, biology, physics.

[4]  Ronald C. Chen,et al.  Prostate Stereotactic Body Radiation Therapy: An Overview of Toxicity and Dose Response. , 2020, International journal of radiation oncology, biology, physics.

[5]  I. Kaplan,et al.  Patient Reported Outcomes in NRG Oncology/RTOG 0938, a Randomized Phase II Study Evaluating 2 Ultrahypofractionated Regimens (UHR) for Prostate Cancer (CaP) , 2020, International Journal of Radiation Oncology*Biology*Physics.

[6]  M. Scorsetti,et al.  Stereotactic Body Radiation Therapy for Intermediate-risk Prostate Cancer With VMAT and Real-time Electromagnetic Tracking: A Phase II Study. , 2020, American journal of clinical oncology.

[7]  M. Zelefsky,et al.  Strict bladder filling and rectal emptying during prostate SBRT: Does it make a dosimetric or clinical difference? , 2020, Radiation oncology.

[8]  K. Haustermans,et al.  Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer. , 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[9]  H. Minn,et al.  Once‐a‐week or every‐other‐day urethra‐sparing prostate cancer stereotactic body radiotherapy, a randomized phase II trial: 18 months follow‐up results , 2020, Cancer medicine.

[10]  Jim C Hu,et al.  Trends in the Use of Stereotactic Body Radiotherapy for Treatment of Prostate Cancer in the United States. , 2020, JAMA network open.

[11]  S. Senan,et al.  A prospective single-arm phase II study of stereotactic magnetic-resonance-guided adaptive radiotherapy for prostate cancer: Early toxicity results. , 2019, International journal of radiation oncology, biology, physics.

[12]  G. Rodrigues,et al.  Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial , 2019, The Lancet. Oncology.

[13]  Paul J Catalano,et al.  Master Protocol Trial Design for Efficient and Rational Evaluation of Novel Therapeutic Oncology Devices , 2019, Journal of the National Cancer Institute.

[14]  L. Beckman,et al.  Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial , 2019, The Lancet.

[15]  A. Kishan,et al.  Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies. , 2019, International journal of radiation oncology, biology, physics.

[16]  M. Zelefsky,et al.  Five-Year Outcomes of a Phase 1 Dose-Escalation Study Using Stereotactic Body Radiosurgery for Patients With Low-Risk and Intermediate-Risk Prostate Cancer. , 2019, International journal of radiation oncology, biology, physics.

[17]  A. Kishan,et al.  Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer , 2019, JAMA network open.

[18]  F. Alongi,et al.  Phase II study of accelerated Linac-based SBRT in five consecutive fractions for localized prostate cancer , 2018, Strahlentherapie und Onkologie.

[19]  Martin G Sanda,et al.  Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors. , 2010, Urology.

[20]  J. Fries,et al.  The Patient-Reported Outcomes Measurement Information System (PROMIS): Progress of an NIH Roadmap Cooperative Group During its First Two Years , 2007, Medical care.